Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant

a polynucleotide and immunogenic composition technology, applied in the field of immunogenic compositions, can solve the problems of ineffective use of polyinosinic acid-polycytidylic acid (pic), one of the most studied polynucleotide complexes, and inability to provide optimal efficacy/safety profile,

Inactive Publication Date:
View PDF27 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Polyinosinic acid-polycytidylic acid (PIC), one of most studied polynucleotide complexes, was not effective when used in monkeys and humans due to its instability in the body after administration.
However, Lin found that that the form of PICKCa originally identified does not provide the optimal efficacy / safety profile for use as an adjuvant and also induces unacceptable adverse side effects under certain conditions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
  • Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
  • Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant

Examples

Experimental program
Comparison scheme
Effect test

example 1

PIKA in Combination with a Variety of Antigens Induces a Specific Immune Response

[0215] This example involves use of PIKA in combination with a variety of antigens to elicit a specific immune response in vivo. The research was conducted in a series of independent experiments with a common protocol though using a different antigen each time. The antigens tested include: a recombinant protein hepatitis B surface antigen type adw, an inactivated split influenza vaccine (VAXIGRIP from Sanofi Pasteur), a synthesized HIV peptide antigen, a recombinant protein herpes simplex virus type 2 gD antigen, recombinant protective anthrax protein antigen, inactivated whole virus avian influenza antigen strain H5N1 and an inactivated whole virus Severe Acute Respiratory Syndrome (SARS) inactivated antigen.

[0216] The protocol for the individual experiment involve the inoculation of Balb / c mice with compositions of antigen alone, antigen with the PIKA adjuvant (a heterogeneous composition of PIKA mo...

example 1.1

Recombinant Hepatitis B Surface Antigen (HBSAg) adw

[0222] The results in table II below are the results of the ELISPOT test detecting the presence number of cells producing INF-γ, IL-2 and IL-4 using a recombinant protein hepatitis B surface antigen (HBsAg) type adw. Groups A to E represent the different combinations of antigen / adjuvant / control media administered to the mice. The numbers in the table II (see also FIG. 1.1) represent the ELISPOT reading, the number of spot forming cells, that is, a direct measure the number of cells producing cytokine.

[0223] The distinct increase in the number of spot forming cells with the addition of the PIKA adjuvant (as compared with the antigen alone) demonstrates that the addition of the PIKA adjuvant to recombinant hepatitis B surface antigen enhances the expression of cytokines INF-γ, IL-2 and IL-4 by cultured spleen cells. The observed expression of cytokines indicates an enhanced adaptive immune response of both a humoral and cell mediate...

example 1.2

VAXIGRIP (Sanofi Pasteur), Inactivated and Purified Influenza Antigen Comprising; H1N1, H3N2 Like Strains and b / Shanghai5 / 361 / 2002 Strain

[0225] The results in table III below are the results of the ELISPOT test detecting the presence the number of cells producing INF-γ, IL-2 and IL-4 using VAXIGRIP vaccine a inactivated split human influenza vaccine produced by Sanofi Pasteur. Groups A to D represent the different combinations of antigen / adjuvant / control media administered to the mice. The numbers in the table III (see also FIG. 1.2) represent the ELISPOT reading, the number of spot forming cells, that is, a direct measure of cytokine production.

[0226] The distinct increase in the number of spot forming cells with the addition of the PIKA adjuvant (as compared with the antigen alone) demonstrates that the addition of the PIKA adjuvant to the influenza antigen enhances the expression of cytokines INF-γ, IL-2 and IL-4 by cultured spleen cells. The observed expression of cytokines in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine). The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response to an antigenic compound.

Description

FIELD OF INVENTION [0001] The invention generally relates to immunogenic compositions and methods of their use. More specifically the invention relates to an immunogenic composition comprising a polynucleotide adjuvant in combination with one or more antigenic substances to be used to elicit disease specific immune response in a host. BACKGROUND OF INVENTION [0002] The immune system may exhibit both specific and nonspecific immunity. Nonspecific immunity encompasses various cells and mechanisms such as phagocytosis (the engulfing of foreign particles or antigens) by macrophages or granulocytes, and natural killer (NK) cell activity, among others. Nonspecific immunity relies on mechanisms less evolutionarily advanced and does not display the acquired nature of specificity and memory, which are exemplary hallmarks of a specific immune response. The key differences between specific and nonspecific immunity are based upon B and T cell specificity. These cells predominantly acquire their...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68C12P19/34
CPCA61K33/00A61K2039/55561A61K45/06A61K39/39A61P31/00A61P31/04A61P31/10A61P31/12A61P31/14A61P31/16A61P31/18A61P31/20A61P31/22A61P33/00A61P35/00A61P37/00A61P37/04Y02A50/30A61K33/06C12P19/34A61K39/00
Inventor LIN, HAIXIANGLI, LIE TAO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap